Baker D - Search Results

1

Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis.

Allen-Philbey K, De Trane S, MacDougall A, Adams A, Bianchi L, Campion T, Giovannoni G, Gnanapavan S, Holden DW, Marta M, Mathews J, Turner BP, Baker D, Schmierer K. Allen-Philbey K, et al. Among authors: baker d. Ther Adv Neurol Disord. 2023 Nov 10;16:17562864231200627. doi: 10.1177/17562864231200627. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 37954917 Free PMC article.

2

Mifepristone or inhibition of 11beta-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Delta(9)-tetrahydrocannabinol in mice.

Pryce G, Giovannoni G, Baker D. Pryce G, et al. Among authors: baker d. Neurosci Lett. 2003 May 1;341(2):164-6. doi: 10.1016/s0304-3940(03)00159-9. Neurosci Lett. 2003. PMID: 12686391

3

The therapeutic potential of cannabis.

Baker D, Pryce G, Giovannoni G, Thompson AJ. Baker D, et al. Lancet Neurol. 2003 May;2(5):291-8. doi: 10.1016/s1474-4422(03)00381-8. Lancet Neurol. 2003. PMID: 12849183 Review.

4

Inflammatory disorders of the central nervous system.

Giovannoni G, Baker D. Giovannoni G, et al. Among authors: baker d. Curr Opin Neurol. 2003 Jun;16(3):347-50. doi: 10.1097/01.wco.0000073936.19076.9c. Curr Opin Neurol. 2003. PMID: 12858072 Review. No abstract available.

5

Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.

Pryce G, Ahmed Z, Hankey DJ, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A, Thompson AJ, Giovannoni G, Cuzner ML, Baker D. Pryce G, et al. Among authors: baker d. Brain. 2003 Oct;126(Pt 10):2191-202. doi: 10.1093/brain/awg224. Epub 2003 Jul 22. Brain. 2003. PMID: 12876144

6

Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis.

Pryce G, O'Neill JK, Croxford JL, Amor S, Hankey DJ, East E, Giovannoni G, Baker D. Pryce G, et al. Among authors: baker d. J Neuroimmunol. 2005 Aug;165(1-2):41-52. doi: 10.1016/j.jneuroim.2005.04.009. J Neuroimmunol. 2005. PMID: 15939483

7

Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis.

Croxford JL, Pryce G, Jackson SJ, Ledent C, Giovannoni G, Pertwee RG, Yamamura T, Baker D. Croxford JL, et al. Among authors: baker d. J Neuroimmunol. 2008 Jan;193(1-2):120-9. doi: 10.1016/j.jneuroim.2007.10.024. Epub 2007 Nov 26. J Neuroimmunol. 2008. PMID: 18037503

8

Evaluating potential therapies for bladder dysfunction in a mouse model of multiple sclerosis with high-resolution ultrasonography.

Al-Izki S, Pryce G, Giovannoni G, Baker D. Al-Izki S, et al. Among authors: baker d. Mult Scler. 2009 Jul;15(7):795-801. doi: 10.1177/1352458509104594. Epub 2009 May 22. Mult Scler. 2009. PMID: 19465448

9

Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis.

Al-Izki S, Pryce G, Jackson SJ, Giovannoni G, Baker D. Al-Izki S, et al. Among authors: baker d. Mult Scler. 2011 Aug;17(8):939-48. doi: 10.1177/1352458511400476. Epub 2011 Apr 1. Mult Scler. 2011. PMID: 21459808

10

Fingolimod modulates microglial activation to augment markers of remyelination.

Jackson SJ, Giovannoni G, Baker D. Jackson SJ, et al. Among authors: baker d. J Neuroinflammation. 2011 Jul 5;8:76. doi: 10.1186/1742-2094-8-76. J Neuroinflammation. 2011. PMID: 21729281 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,806 results

Search Page

Filters